anti-EGFR immunoliposomes loaded with doxorubicin

Anti-EGFR immunoliposomes loaded with doxorubicin are a targeted nanomedicine designed for the treatment of cancers that overexpress the epidermal growth factor receptor (EGFR). This formulation consists of pegylated liposomes encapsulating the chemotherapeutic agent doxorubicin. The surface of these liposomes is functionalized with antibody fragments derived from cetuximab (C225), which specifically bind to EGFR on tumor cells. Upon binding, the immunoliposome is internalized by EGFR-expressing cancer cells, enabling intracellular release of doxorubicin and enhancing cytotoxicity while aiming to reduce off-target toxicity. The drug has been evaluated in phase I and II clinical trials for advanced solid tumors and triple-negative breast cancer (TNBC) expressing EGFR[2][5][8]. It has also been studied in relapsed or refractory high-grade gliomas[1][6]. While early-phase studies showed manageable toxicity and some efficacy signals, a phase II trial in TNBC did not meet its primary endpoint for progression-free survival at 12 months[2][8].

Other names

doxorubicin-loaded anti-EGFR immunoliposomesIL-C225IL-C-225IL-C 225DXR-IL-C225DXR-IL-C-225DXR-IL-C 225